250 related articles for article (PubMed ID: 19596970)
41. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
[TBL] [Abstract][Full Text] [Related]
42. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
Rao G; Crispens M; Rothenberg ML
J Clin Oncol; 2007 Jul; 25(20):2867-72. PubMed ID: 17617517
[TBL] [Abstract][Full Text] [Related]
43. Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
Armstrong DK; Coleman RL; Penson RT
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 5):1-16. PubMed ID: 21558997
[TBL] [Abstract][Full Text] [Related]
44. [Gynecologic cancer].
Uehara T; Katsumata N
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1488-94. PubMed ID: 18799902
[TBL] [Abstract][Full Text] [Related]
45. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
46. The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.
Vernooij F; Witteveen PO; Verweij E; van der Graaf Y; Heintz AP
Gynecol Oncol; 2009 Dec; 115(3):343-8. PubMed ID: 19800674
[TBL] [Abstract][Full Text] [Related]
47. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
48. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
49. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
50. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
51. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
52. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
Vergote I; Amant F; Leunen K; Cadron I; Van Gorp T; Neven P; Berteloot P
Oncologist; 2008 Apr; 13(4):410-4. PubMed ID: 18448555
[TBL] [Abstract][Full Text] [Related]
53. Targeting signaling pathways in ovarian cancer.
Reibenwein J; Krainer M
Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
[TBL] [Abstract][Full Text] [Related]
54. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
55. Centering prayer for women receiving chemotherapy for recurrent ovarian cancer: a pilot study.
Johnson ME; Dose AM; Pipe TB; Petersen WO; Huschka M; Gallenberg MM; Peethambaram P; Sloan J; Frost MH
Oncol Nurs Forum; 2009 Jul; 36(4):421-8. PubMed ID: 19581232
[TBL] [Abstract][Full Text] [Related]
56. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
[TBL] [Abstract][Full Text] [Related]
57. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
Naumann RW; Sukumvanich P; Edwards RP
Gynecol Oncol; 2009 Jul; 114(1):37-41. PubMed ID: 19410281
[TBL] [Abstract][Full Text] [Related]
58. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
59. Controversies in the management of ovarian cancer--pros and cons for lymph node dissection in ovarian cancer.
Camara O; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2837-43. PubMed ID: 19596971
[TBL] [Abstract][Full Text] [Related]
60. [Clinical impact of locoregional hyperthermia in gynecological oncology].
Bischoff J; Lindner LH; Issels RD; Costa S
Zentralbl Gynakol; 2006 Oct; 128(5):255-60. PubMed ID: 17001560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
